Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 11—November 2022
Research Letter

Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak

Matthew Turner, Jeremy Mandia1, Case Keltner1, Robert Haynes1Comments to Author , Paul Faestel, and Luke Mease
Author affiliation: Madigan Army Medical Center, Tacoma, Washington, USA

Main Article

Figure

Evolution of penile lesions in patient who had monkeypox and was immunized with ACAM2000 smallpox vaccine during 2022 monkeypox outbreak, United States. A) Two days after constitutional symptoms developed; B) evolution of rash showing coalescence and development of a pustular appearance 6 days after onset of constitutional symptoms; C) ulceration of lesion on day 16; D) dissipation of lesion without residual scarring.

Figure. Evolution of penile lesions in patient who had monkeypox and was immunized with ACAM2000 smallpox vaccine during 2022 monkeypox outbreak, United States. A) Two days after constitutional symptoms developed; B) evolution of rash showing coalescence and development of a pustular appearance 6 days after onset of constitutional symptoms; C) ulceration of lesion on day 16; D) dissipation of lesion without residual scarring.

Main Article

1These authors contributed equally to this article.

Page created: September 14, 2022
Page updated: October 24, 2022
Page reviewed: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external